- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07369869
Evaluatie van de effecten van prebiotica- en vezelinterventies op slaap, het darmmicrobioom, cognitie en stress.
Evaluating the Effects of Nutritional Interventions on Sleep, the Gut Microbiome, Cognition, and Stress
This will be a double-blind, placebo-controlled, parallel-group trial. Participants who are poor sleepers will be randomised to receive one of two investigational supplements, or a placebo control supplement, over a 28-day period. At baseline and following 28 days of consumption, sleep quality, gut microbiome profiles, cognitive performance, and mood will be assessed. Sleep outcome measures will also be assessed throughout the supplementation period to monitor the time course of any observed changes. A final data set of at least 66 participants is expected.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
This will be a double-blind, placebo-controlled, parallel-group trial. Participants who are poor sleepers will be randomised to receive one of two investigational supplements, or a placebo control supplement, over a 28-day period. At baseline and following 28 days of consumption, sleep quality, gut microbiome profiles, cognitive performance, and mood will be assessed. Sleep outcome measures will also be assessed throughout the supplementation period to monitor the time course of any observed changes. A final data set of at least 66 participants is expected.
Interested participants will initially be scheduled to complete a screening telephone call with the researcher. Here, electronic informed consent will first be provided by the participant, by accessing a pre-emailed link to the Qualtrics survey platform, to an account which is hosted by Northumbria University. Once consent is obtained, the participant will confirm that they do not meet any of the study exclusion criteria, and will complete the SDS-CL checklist with the researcher, over the phone. If any clinical thresholds are met, participants will be invited to a separate clinical interview (again via phonecall) with Professor Jason Ellis, employing the International Classification of Sleep Disorders (ICSD-3) criteria, to determine elligibility.
If participants progress to enrolment, they will be invited to attend a lab-based training/screening session (protocol day -7) at Northumbria University. Here, hard and wet-signed (by both the participant and the researcher) consent forms will be completed and stored on site. Participants will then be familiarised with the study protocol and procedures. Participants will also be trained on the cognitive tasks. During the following 7 nights (Protocol days -7 to -1), participants will monitor their sleep and complete the daily Sleep Diary each morning. During this week, they will also drop off their pre-dose baseline stool sample at a remote drop-off location at Northumbria University.
Seven days following the lab-based screening visit (Supplement day 1, Protocol day 0), participants will attend the laboratory for their acute visit. Here, a pre-dose baseline sample of saliva and a single blood sample will be taken (for Alpha Amylase, Cortisol, Serotonin and Melatonin), and Blood Pressure, Heart Rate, Body Mass Index, and Waist-to-Hip Ratio will be measured. Participants will complete the Intake24 dietary assessment, and gastrointestinal symptoms questionnaires, as well as the Pittsburgh Sleep Quality Index (PSQI), State-Trait Anxiety Inventory (STAI), and Depression, Anxiety and Stress Scale - 21 Items (DASS-21). The cognitive task battery will additionally be completed.
After completing these measures, participants will receive instructions on the next phase of the trial. From that night, participants will consume their first dose of the investigational supplement (noting the time in their treatyment diary) 4 hours before their normal bed-time. They will monitor their sleep overnight. The following morning (supplementation day 2, protocol day 1), participants will complete their Sleep Diary. Participants will follow this procedure for the following 27 days. At some point during Protocol (Days 12-18), participants will return to Northumbria University to drop-off their interim stool sample.
On Protocol day 28, participants will return to the lab for the chronic testing visit. All of the outcome measures assessed during the acute lab visit (Protocol day 0) will be repeated here. At the end of the session, participants will be debriefed, and their participation payment arranged. At some point during Protocol (Days 27-33) participants will return to Northumbria University to drop-off their chronic stool sample.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Newcastle upon Tyne, Verenigd Koninkrijk
- Northumbria University- Northumbria Sleep center and NUTRAN
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
INCLUSION CRITERIA
- Participants must self-assess themselves as being in good health.
- Aged 25 to 60 years at the time of randomisation
- Fluent in English
- Identify as a 'poor sleeper' as defined subjectively (i.e. poor sleep quality, unrefreshing sleep) and a total score of >5 on the Pittsburgh Sleep Quality Index (PSQI).
EXCLUSION CRITERIA
- Member of own household currently participating in this trial
- Evidence of current or recent sleep disorders (e.g. sleep apnoea, insomnia, circadian rhythm disorders), taking any medication which exerts sedative effects, affects the CNS and/or sleep, or be currently unwell with any illness that affects sleep (i.e. disorders of the CNS). An initial screening for sleep disorders will be conducted using the Sleep Disorders Symptom Checklist-25 (SDS-CL; Klingman et al., 2017). If a participant reports positively to any of the 25 questions in terms of being affected for three nights per week, or more, this will be followed up using a clinical interview according to the International Classification of Sleep Disorders (ICSD-3) to exclude on the basis of a sleep disorder
- History of seizures or epilepsy
- Shift working or have a history of shift work within the previous six months
- Currently, or within the previous 8 weeks, consuming any nutritional supplements.
- Participation in any other intervention research trials
- Sleeping at a location other than their usual residence more than two nights per week during participation
- Travel across multiple time zones within the last three months or have planned travel across multiple time zones during the study
- Current or recent mood disturbances or Axis I disorders (descriptions will be given)
- Current misuse of alcohol and/or drugs
- Current smoker
- Recent (within the last 12 weeks) infection and/or use of antibiotic medication
- Pregnant, seeking to become pregnant or lactating
- Those using (including within the last 2 weeks) proton-pump inhibitors
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm 1
Participants will be randomly allocated to consume investigational supplement (1 of 2 proprietary 'active' compositions) for 28 days. |
A proprietary orally administered dietary supplement consisting of standardized ingredients. |
|
Experimenteel: Arm 2
Participants will be randomly allocated to consume investigational supplement (1 of 2 proprietary 'active' compositions) for 28 days. |
A proprietary orally administered dietary supplement consisting of standardized ingredients. |
|
Placebo-vergelijker: Control
Participants will be randomly allocated to consume control supplement for 28 days. |
Flavored vehicle |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Sleep Efficiency (SE)
Tijdsspanne: Change from Baseline to end of supplementation period at 28 days
|
Sleep efficiency (SE), commonly defined as the ratio of total sleep time (TST) to time in bed (TIB), will be reported as a percentage of time in bed. |
Change from Baseline to end of supplementation period at 28 days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Actigraphy - Sleep onset latency
Tijdsspanne: Change from baseline following 28 days of supplement consumption
|
recorded minutes taken from intention to sleep to sleep initiation |
Change from baseline following 28 days of supplement consumption
|
|
Actigraphy - Sleep efficiency
Tijdsspanne: Change from baseline following 28 days of supplement consumption
|
ratio of the total time spent asleep (total sleep time) in a night compared to the total amount of time spent in bed (percentage) |
Change from baseline following 28 days of supplement consumption
|
|
Actigraphy - Number of awakenings
Tijdsspanne: Change from baseline following 28 days of supplement consumption
|
recorded number of awakenings during entire sleep period |
Change from baseline following 28 days of supplement consumption
|
|
Actigraphy - Wake after sleep onset (WASO)
Tijdsspanne: Change from baseline following 28 days of supplement consumption
|
recorded minutes awake during the entire sleep period following sleep onset |
Change from baseline following 28 days of supplement consumption
|
|
COMPASS global performance measures
Tijdsspanne: Change from baseline following 28 days of supplement consumption
|
Speed of performance, and accuracy of performance measured by Computerised Mental Performance Assessment System (COMPASS, Northumbria University) |
Change from baseline following 28 days of supplement consumption
|
|
Pittsburgh Sleep Quality Index (PSQI)
Tijdsspanne: Change from baseline following 28 days of supplement consumption
|
Pittsburgh Sleep Quality Index (PSQI): Total Score. The PSQI is a validated self-rating instrument assessing aspects of sleep quality.Minimum score 0 (better); maximum score 21 (worse) < or = 5 associated with good sleep quality; > 5 associated with poor sleep quality. |
Change from baseline following 28 days of supplement consumption
|
|
Depression, Anxiety and Stress Scale - 21 Items (DASS-21)
Tijdsspanne: Change from baseline following 28 days of supplement consumption
|
A 21-item measure of mood over the previous week (each item is rated on scale from 0-3). Scoring creates 3 component scores: depression, anxiety and stress (each on a scale of 0-21) with higher scores indicating higher symptomology. Cut-off scores, according to each set of symptoms, are available (normal, mild, moderate, severe and extremely severe) or total scores can be derived by multiplying the sum of all three component scores by 2. |
Change from baseline following 28 days of supplement consumption
|
|
State-Trait Anxiety Inventory (STAI)
Tijdsspanne: Change from baseline following 28 days of supplement consumption
|
A 40-item measure of current and general anxiety levels. Each item is rated on a scale from 1-4. Scoring creates two components: state anxiety (20 items) and trait anxiety (20 items), with a range for each between 20-80. Following transformation through reversed coding, higher scores indicate higher levels of anxiety |
Change from baseline following 28 days of supplement consumption
|
|
Actigraphy - Total sleep time
Tijdsspanne: Change from baseline following 28 days of supplement consumption
|
recorded minutes asleep over entire sleep period |
Change from baseline following 28 days of supplement consumption
|
|
Sleep Diary - Total sleep time
Tijdsspanne: Change from baseline following 28 days of supplement consumption
|
recorded minutes asleep over entire sleep period |
Change from baseline following 28 days of supplement consumption
|
|
Sleep Diary - Sleep onset latency
Tijdsspanne: Change from baseline following 28 days of supplement consumption
|
logged minutes taken from intention to sleep to sleep initiation |
Change from baseline following 28 days of supplement consumption
|
|
Sleep Diary - Sleep efficiency
Tijdsspanne: Change from baseline following 28 days of supplement consumption
|
ratio of the total time spent asleep (total sleep time) in a night compared to the total amount of time spent in bed (percentage) |
Change from baseline following 28 days of supplement consumption
|
|
Sleep Diary - Number of awakenings
Tijdsspanne: Change from baseline following 28 days of supplement consumption
|
logged number of awakenings during entire sleep period |
Change from baseline following 28 days of supplement consumption
|
|
Sleep Diary - Wake after sleep onset (WASO)
Tijdsspanne: Change from baseline following 28 days of supplement consumption
|
logged minutes awake during the entire sleep period following sleep onset |
Change from baseline following 28 days of supplement consumption
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Professor Jason Ellis, PhD, Northumbria University
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- 000000
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .